Butterfly Network Shares Surge 20.65% Amid New SEC Filings and Homecare Pilot
By ATTN Desk · Editorial oversight: Sean Han
Introduction
Butterfly Network Inc (NYS: BFLY) is a Burlington, Massachusetts–based medical technology company founded in 2011. Utilizing its patented Ultrasound-on-Chip™ platform, Butterfly offers single-probe, whole-body point-of-care ultrasound (POCUS) solutions that integrate handheld probes with software and workflow tools. The company aims to make ultrasound imaging accessible in various care settings.
Corporate Structure
Butterfly Network employs between 51 and 200 people across research and development, engineering, sales, and customer support. The company has adopted a hybrid work model, with many employees working in Burlington or New York City offices at least two days per week. Its internal culture emphasizes focus, dedication, and innovation, supported by:
- 100% employer-paid base medical, dental, and vision coverage from day one
- Annual HSA contributions and pre-tax savings accounts
- Immediate vesting on 401(k) matching and an Employee Stock Purchase Plan
- Flexible paid time off, parental leave, and life/disability insurance
Ultrasound Technology by National Cancer Institute
Developments and News
- November 18, 2025: Filed an 8-K (Acc-no: 0001804176-25-000015) under Items 1.01 and 9.01. Specific details were not disclosed.
- October 31, 2025:
- Filed a 10-Q for Q3 ending September 30, 2025 (Acc-no: 0001804176-25-000009), covering quarterly financial results.
- Registered 10,651,753 additional shares under the S-8 filing (Acc-no: 0001804176-25-000011) for equity incentive and employee purchase plans, reflecting the "evergreen" provisions of its 2020 and 2024 plans.
- November 19, 2025: BFLY shares closed at $2.4250, representing a 20.65% increase on a volume of 5,321,123 shares traded.
- November 19, 2025: Hosted a webinar for anesthesiology professionals focusing on POCUS applications.
- March 17, 2025: William Blair initiated coverage, projecting revenues of $97.0 million for 2025 and $115.4 million for 2026, with a target of cash-flow breakeven by end-2027.
Financial and Strategic Analysis
As of November 19, 2025, Butterfly's trailing twelve-month (TTM) figures are as follows:
| Metric | Value |
|---|---|
| Market Capitalization | $507.73 M |
| Enterprise Value | $384.53 M |
| TTM Revenue | $88.45 M |
| Net Income (TTM) | –$79.87 M |
| Diluted EPS (TTM) | –0.33 |
| Price/Sales (TTM) | 5.28× |
| Price/Book (mrq) | 2.44× |
| Total Cash (mrq) | $144.23 M |
| Total Debt/Equity (mrq) | 10.32% |
The company invests in research and development, shown by its product evolution from the iQ probe (2018) to iQ+ (2020) and iQ3 (2024). Additionally, Butterfly has developed a software ecosystem that incorporates AI-powered image analysis and workflow management tools. In late 2024, the company established Octiv, a subsidiary focused on leveraging its intellectual property in adjacent markets. It is also initiating a pilot program for homecare services, starting with lung and bladder scanning.
Market Position and Industry Context
Butterfly operates within a global POCUS market expected to surpass $3 billion by 2028. Its semiconductor-based ultrasound technology presents advantages over traditional piezoelectric probes, including reduced manufacturing costs and simplified maintenance. The company serves over 145,000 customers, including both human and veterinary practices. It positions itself as a provider of both hardware innovations and integrated software solutions. Its partnerships extend across hospital networks, animal health distributors, and remote care initiatives in underserved regions.
tl;dr
As of November 19, 2025, Butterfly Network’s stock increased by 20.65% to $2.425, with a trading volume of over 5.3 million shares. Key SEC filings on October 31 included a 10-Q and an S-8, which registered over 10.6 million shares for employee programs. The company reported TTM revenue of $88.45 million with a net loss of $79.87 million and cash reserves of $144.23 million. William Blair estimates revenue at $97 million in 2025, targeting breakeven by 2027. Initiatives such as the homecare pilot and the Octiv subsidiary are expected to expand market opportunities.